logo
logo
Acadia Healthcare Company, Inc.

Acadia Healthcare Company, Inc.

NASDAQ•ACHC
CEO: Mr. Christopher Howal Hunter
セクター: Healthcare
業種: Medical - Care Facilities
上場日: 1994-03-04
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
連絡先情報
6100 Tower Circle, Suite 1000, Franklin, TN, 37067, United States
615-861-6000
www.acadiahealthcare.com
時価総額
$1.48B
PER (TTM)
13.8
33.5
配当利回り
--
52週高値
$42.85
52週安値
$11.43
52週レンジ
16%
順位46Top 59.5%
3.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$851.57M+4.41%
直近4四半期の推移

EPS

$0.40-45.95%
直近4四半期の推移

フリーCF

-$63.03M+132.49%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Nine month revenue reached $2.491B, marking 4.7% growth compared to prior year period.
Operating Cash Flow Surge Cash provided by operations totaled $218.2M for nine months, significantly up from $13.0M last year.
Total Assets Increase Total assets grew to $6.413B as of September 30, 2025, up from $5.957B at year-end 2024.
Facility Bed Expansion Added 908 beds in nine months through existing facility expansions and new wholly-owned/joint venture openings.

リスク要因

Net Income Profit Decline Net income attributable to stockholders fell to $74.7M for nine months, down from $223.0M previously.
Investigation Cost Impact Government investigation costs drove transaction costs to $138.4M for nine months, impacting period results.
Ongoing Legal Exposure Multiple securities and derivative lawsuits remain pending; ultimate liability estimation is currently not possible.
Labor Market Pressures Navigating tight labor market with higher wage inflation, focusing on staffing levels across 40 states.

見通し

New Credit Facility Active New $1.0B Revolving and $650.0M Term Loan Credit Facility closed February 2025, refinancing prior debt.
Growth Strategy Focus Strategy centers on five pathways: expansions, joint ventures, de novo facilities, acquisitions, and service continuum growth.
Share Repurchase Program $300.0M share repurchase program authorized; $250.0M remains available for purchases as of September 30, 2025.
Medicaid Financing Changes Monitoring OBBBA changes starting 2028 regarding provider tax arrangements and state directed payment caps.

同業比較

売上高 (TTM)

Bausch Health Companies Inc.BHC
$10.03B
+5.9%
Ardent Health Partners, Inc.ARDT
$6.33B
+10.9%
Select Medical Holdings CorporationSEM
$3.93B
-35.0%

粗利益率 (最新四半期)

Acadia Healthcare Company, Inc.ACHC
96.4%
+0.1pp
Inspire Medical Systems, Inc.INSP
86.6%
+1.8pp
Bausch Health Companies Inc.BHC
72.0%
-0.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
BKD$3.96B-14.8-229.8%0.0%
HAE$2.74B15.620.3%49.2%
LFST$2.74B-298.8-0.6%22.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.2%
緩やかな成長
4四半期純利益CAGR
3.6%
収益性の緩やかな改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月25日
|
EPS:$0.03
|
売上高:$800.10M
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $851.57M+4.4%
    |
    EPS: $0.40-45.9%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $869.23M+9.2%
    |
    EPS: $0.33-61.6%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月12日|
    売上高: $770.51M+0.3%
    |
    EPS: $0.09-89.3%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $3.15B+7.7%
    |
    EPS: $2.79+1262.5%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月30日|
    売上高: $815.63M+8.7%
    |
    EPS: $0.74-131.0%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月1日|
    売上高: $796.04M+8.8%
    |
    EPS: $0.86+8.9%
    予想通り

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $768.05M+9.1%
    |
    EPS: $0.84+15.1%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月28日|
    売上高: $2.93B+12.2%
    |
    EPS: $-0.24-107.9%
    予想を下回る